HighVista Strategies LLC Raises Stock Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

HighVista Strategies LLC grew its holdings in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 4.5% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 33,305 shares of the specialty pharmaceutical company’s stock after purchasing an additional 1,432 shares during the period. HighVista Strategies LLC owned about 0.08% of KalVista Pharmaceuticals worth $386,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Great Point Partners LLC purchased a new stake in KalVista Pharmaceuticals during the second quarter worth about $15,768,000. Vestal Point Capital LP increased its stake in shares of KalVista Pharmaceuticals by 73.9% during the third quarter. Vestal Point Capital LP now owns 4,000,000 shares of the specialty pharmaceutical company’s stock worth $46,320,000 after buying an additional 1,700,000 shares during the period. Emerald Advisers LLC increased its stake in shares of KalVista Pharmaceuticals by 29.8% during the third quarter. Emerald Advisers LLC now owns 835,988 shares of the specialty pharmaceutical company’s stock worth $9,681,000 after buying an additional 192,091 shares during the period. The Manufacturers Life Insurance Company increased its stake in shares of KalVista Pharmaceuticals by 27.3% during the second quarter. The Manufacturers Life Insurance Company now owns 15,437 shares of the specialty pharmaceutical company’s stock worth $182,000 after buying an additional 3,314 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its stake in shares of KalVista Pharmaceuticals by 4.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 22,142 shares of the specialty pharmaceutical company’s stock worth $263,000 after buying an additional 944 shares during the period.

KalVista Pharmaceuticals Stock Down 5.3 %

Shares of KalVista Pharmaceuticals stock opened at $9.73 on Wednesday. The firm has a market capitalization of $420.53 million, a P/E ratio of -2.76 and a beta of 0.85. KalVista Pharmaceuticals, Inc. has a 52 week low of $7.39 and a 52 week high of $16.88. The firm’s 50 day moving average is $10.96 and its two-hundred day moving average is $11.89.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its quarterly earnings results on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) EPS for the quarter, beating the consensus estimate of ($0.91) by $0.04. As a group, research analysts expect that KalVista Pharmaceuticals, Inc. will post -2.7 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Benjamin L. Palleiko sold 14,400 shares of the stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $9.26, for a total value of $133,344.00. Following the completion of the sale, the chief executive officer now directly owns 266,598 shares of the company’s stock, valued at approximately $2,468,697.48. This represents a 5.12 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Paul K. Audhya sold 8,077 shares of the stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $9.26, for a total value of $74,793.02. Following the completion of the sale, the insider now directly owns 94,199 shares of the company’s stock, valued at $872,282.74. The trade was a 7.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 32,016 shares of company stock valued at $319,344. 10.50% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Needham & Company LLC restated a “buy” rating and set a $32.00 target price on shares of KalVista Pharmaceuticals in a research note on Friday, September 6th. HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of KalVista Pharmaceuticals in a research note on Monday, October 7th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of KalVista Pharmaceuticals in a research note on Monday, September 9th.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).